Home > News > Freeing nanodevices from the constraints of ATP
September 26th, 2004
Freeing nanodevices from the constraints of ATP
Engineers expect that tomorrow's nanomachines - biomolecular devices that might patrol cells, repair genes, scour out infections, and haul away debris - will be powered by nature's own motors: the proteins kinesin, myosin, and dynein, which turn adenosine triphosphate (ATP) into fuel and move loads along microtubular tracks of actin and tubulin.
It makes sense to use these off-the-shelf engines as they're 1,000 times smaller than anything humans can yet build. But recent research indicates that by the time bioengineers are ready to begin assembling their intracellular delivery vehicles, they will have a wider range of motors to choose from.
Nanotechnology in Medical Devices Market is expected to reach $8.5 Billion by 2019 March 25th, 2015
Nanotechnology Enabled Drug Delivery to Influence Future Diagnosis and Treatments of Diseases March 21st, 2015
Nanocomposites Market Growth, Industry Outlook To 2020 by Grand View Research, Inc. March 21st, 2015
Nanotechnology Drug Delivery Market in the US 2012-2016 : Latest Report Available by Radiant Insights, Inc March 16th, 2015
Designer's toolkit for dynamic DNA nanomachines: Arm-waving nanorobot signals new flexibility in DNA origami March 27th, 2015
Tiny bio-robot is a germ suited-up with graphene quantum dots March 24th, 2015
New remote control for molecular motors: It is now theoretically possible to remotely control the direction in which magnetic molecules spin, which opens the door to designing applications based on molecular motors March 16th, 2015
Monitoring the real-time deformation of carbon nanocoils under axial loading February 18th, 2015